Biocon Pharma Secures FDA Approval for Everolimus Tablets Across Multiple Strengths

Biocon’s latest US FDA approval for Everolimus tablets underscores its momentum in complex, vertically integrated drug products and adds depth to its US generics franchise. Company communications highlight tablet strengths of 0.25 mg to 1 mg; a fresh update references tablets for oral suspension in 2 mg to 5 mg strengths, indicating portfolio breadth.

Key highlights:

• Approved product: Everolimus tablets (ANDA), adding a complex immunosuppressant/oncology asset to Biocon’s US pipeline.
• Strengths referenced: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg (company statement); tablets for oral suspension at 2 mg, 3 mg, 5 mg (recent update).
• Clinical use (per company note): Prophylaxis of organ rejection in adult kidney and liver transplant patients; broader TSC-related indications noted for the oral suspension format.
• Strategic impact: Enhances Biocon’s US footprint in complex generics and supports revenue mix diversification.

Sources: Biocon company statement; Business Standard; InvestyWise